The Korean journal of internal medicine

  • 제26권1호
  • /
  • Pages.54-59
  • /
  • 2011
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Treatment Outcome of Combination Therapy Including Clarithromycin for Mycobacterium avium Complex Pulmonary Disease

  • Kim, Eun-Young (Department of Internal Medicine, Chonnam National University Hospital) ;
  • Chi, Su-Young (Department of Internal Medicine, Chonnam National University Hospital) ;
  • Oh, In-Jae (Department of Internal Medicine, Chonnam National University Hospital) ;
  • Kim, Kyu-Sik (Department of Internal Medicine, Chonnam National University Hospital) ;
  • Kim, Yu-Il (Department of Internal Medicine, Chonnam National University Hospital) ;
  • Lim, Sung-Chul (Department of Internal Medicine, Chonnam National University Hospital) ;
  • Kim, Young-Chul (Department of Internal Medicine, Chonnam National University Hospital) ;
  • Kwon, Yong-Soo (Department of Internal Medicine, Chonnam National University Hospital)
  • 발행 : 2011.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: The frequency of nontuberculous mycobacteria pulmonary disease in HIV-negative patients is increasing; the most common pathogen in Korea is the Mycobacterium avium complex (MAC). However, few studies have evaluated the treatment outcome of MAC pulmonary disease in Korea. Methods: The efficacy of a clarithromycin-containing regimen for MAC pulmonary disease was studied in 42 patients treated for more than 6 months between January 2005 and December 2008. All patients were treated with a regimen consisting of clarithromycin, rifampin, and ethambutol. Streptomycin was added in 10 patients. Results: Among the 42 patients, a negative culture conversion was achieved in 33 (78.6%), and the median duration of treatment in these patients was 19 months (interquartile range [IQR], 16 to 22). Of the 33 patients with a negative culture conversion, 14 completed treatment. During the follow-up period (median, 10 months; IQR, 4 to 20) for the 14 patients, one relapsed at 24 months after treatment completion. The culture conversion rate was significantly higher in patients who were treated with more than 500 mg/day clarithromycin (87.1% vs. 54.5%, p = 0.038). Conclusions: The combined regimen including clarithromycin was effective against MAC pulmonary disease. High-dose clarithromycin of more than 500 mg/day may improve the outcome of patients with MAC pulmonary disease.

키워드

참고문헌

  1. Koh WJ, Kwon OJ, Jeon K, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-348. https://doi.org/10.1378/chest.129.2.341
  2. Lee JY, Choi HJ, Lee H, et al. Recovery rate and characteristics of nontuberculous mycobacterial isolates in a university hospital in Korea. Tuberc Respir Dis 2005;58:385-391. https://doi.org/10.4046/trd.2005.58.4.385
  3. Choi SP, Lee BK, Min JH, Kim JH. Pathogenic classification and clinical characteristics of nontuberculous mycobacterial pulmonary disease in a National Tuberculosis Hospital. Tuberc Respir Dis 2005;59:606-612. https://doi.org/10.4046/trd.2005.59.6.606
  4. Koh WJ, Kwon OJ. Diagnosis and treatment of nontuberculous mycobacterial lung disease. Korean J Med 2008;74:120-131.
  5. Jeon K, Koh WJ, Kwon OJ, et al. Usefulness of bronchoscopy for the diagnosis of nontuberculous mycobacterial pulmonary disease. Tuberc Respir Dis 2004;57:242-249. https://doi.org/10.4046/trd.2004.57.3.242
  6. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416. https://doi.org/10.1164/rccm.200604-571ST
  7. Korean Academy of Tuberculosis and Respiratory Disease. Guidelines for the management of tuberculosis. Seoul: Korean Academy of Tuberculosis and Respiratory Disease, 2005.
  8. Koh WJ, Kwon OJ, Kang EH, et al. Treatment of Mycobacterium avium complex (MAC) pulmonary disease. Tuberc Respir Dis 2004;57:234-241. https://doi.org/10.4046/trd.2004.57.3.234
  9. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161(4 Pt 1):1376-1395. https://doi.org/10.1164/ajrccm.161.4.16141
  10. Kee SJ, Kim SM, Kim SH, et al. Multiplex PCR assay for identification of mycobacterial species isolated from liquid cultures. Chonnam Med J 2009;45:19-26. https://doi.org/10.4068/cmj.2009.45.1.19
  11. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS: Clarithromycin Study Group of France. Chest 1995;107:1035-1040. https://doi.org/10.1378/chest.107.4.1035
  12. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996;153(6 Pt 1):1766-1772. https://doi.org/10.1164/ajrccm.153.6.8665032
  13. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004;126:566-581. https://doi.org/10.1378/chest.126.2.566
  14. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to highdose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993;16:215-221. https://doi.org/10.1016/0732-8893(93)90112-K
  15. Carter G, Young LS, Bermudez LE. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. Antimicrob Agents Chemother 2004;48:4907-4910. https://doi.org/10.1128/AAC.48.12.4907-4910.2004
  16. Hasegawa N, Nishimura T, Watabnabe M, et al. Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease. Pulm Pharmacol Ther 2009;22:190-193. https://doi.org/10.1016/j.pupt.2008.11.004
  17. Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. Respiration 2007;74:394-400 https://doi.org/10.1159/000095674
  18. Hasegawa N, Nishimura T, Ohtani S, et al. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 2009;136:1569-1575. https://doi.org/10.1378/chest.08-2567
  19. Fujikane T, Fujiuchi S, Yamazaki Y, et al. Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. Int J Tuberc Lung Dis 2005;9:1281-1287.
  20. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999;160:866-872. https://doi.org/10.1164/ajrccm.160.3.9811086
  21. Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;173:1283-1289. https://doi.org/10.1164/rccm.200509-1531OC
  22. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997;156(2 Pt 2):S1-S25. https://doi.org/10.1164/ajrccm.156.2.atsstatement

피인용 문헌

  1. Diagnosis and treatment of nontuberculous mycobacterial lung disease vol.54, pp.10, 2011, https://doi.org/10.5124/jkma.2011.54.10.1053
  2. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease vol.82, pp.3, 2011, https://doi.org/10.3904/kjm.2012.82.3.274
  3. Therapeutic Drug Monitoring in the Treatment of Mycobacterium avium Complex Lung Disease vol.186, pp.8, 2011, https://doi.org/10.1164/rccm.201206-1088oc
  4. A Case of Vertebral Osteomyelitis With Epidural Abscess Caused by Mycobacterium intracellulare in a Rheumatoid Arthritis Patient vol.17, pp.3, 2013, https://doi.org/10.4235/jkgs.2013.17.3.138
  5. The influence of environmental exposure on the response to antimicrobial treatment in pulmonary Mycobacterial avium complex disease vol.14, pp.None, 2011, https://doi.org/10.1186/1471-2334-14-522
  6. Respiratory Review of 2014: Tuberculosis and Nontuberculous Mycobacterial Pulmonary Disease vol.77, pp.4, 2014, https://doi.org/10.4046/trd.2014.77.4.161
  7. Serum concentrations of clarithromycin and rifampicin in pulmonary Mycobacterium avium complex disease: long-term changes due to drug interactions and their association with clinical outcomes vol.1, pp.None, 2011, https://doi.org/10.1186/s40780-015-0029-0
  8. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. vol.191, pp.1, 2011, https://doi.org/10.1164/rccm.201408-1545oc
  9. Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists’ point of view vol.10, pp.9, 2011, https://doi.org/10.2217/fmb.15.64
  10. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment vol.46, pp.5, 2011, https://doi.org/10.1183/13993003.00649-2015
  11. Clarithromycin ion pair in a liposomal membrane to improve its stability and reduce its irritation caused by intravenous administration vol.13, pp.3, 2016, https://doi.org/10.1517/17425247.2016.1123247
  12. Infectious Causes of Right Middle Lobe Syndrome vol.24, pp.1, 2011, https://doi.org/10.1177/107327481702400110
  13. Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis vol.65, pp.7, 2017, https://doi.org/10.1093/cid/cix517
  14. Nontuberculous mycobacterial infection in rheumatoid arthritis patients: a single-center experience in South Korea vol.32, pp.6, 2017, https://doi.org/10.3904/kjim.2015.357
  15. Quantitative analysis of Mycobacterium avium subsp. hominissuis proteome in response to antibiotics and during exposure to different environmental conditions vol.16, pp.1, 2019, https://doi.org/10.1186/s12014-019-9260-2
  16. Antibiotic therapy success rate in pulmonary Mycobacterium avium complex: a systematic review and meta-analysis vol.18, pp.3, 2020, https://doi.org/10.1080/14787210.2020.1720650